| Name: | Dexamethasone sodium phosphate EP Impurity E |
| Catalogue No. | VE006239 |
| CAS No. | N/A |
| Molecular Formula | C22H30FO8P |
| Molecular Weight | 472.4 |
| Status | In-stock |
| IUPAC Name | ((2S,3R,4aS,4bS,10aS,10bR,11S,12aS)-10b-fluoro-2,11-dihydroxy-3,10a,12a-trimethyl-1,8-dioxo-1,2,3,4,4a,4b,5,6,8,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl)methyl dihydrogen phosphate |
| Description | Dexamethasone sodium phosphate EP Impurity E is a metabolite of Dexamethasone is a drug of choice for treating patients affected by COVID-19 virus and resulted in lowering 28-day mortality amongst the patients receiving invasive mechanical ventilation or oxygen alone at randomization. |
| References | Ishidax, T., et al. “Terpenoids Biotransformation in Mammals III: Biotransformation of α-Pinene, β-Pinene, Pinane, 3-Carene, Carane, Myrcene, and P-Cymene in Rabbits.” Journal of Pharmaceutical Sciences, vol. 70, no. 4, Apr. 1981, pp. 406–15,https://doi.org/10.1002/jps.2600700417.“Dexamethasone in Hospitalized Patients with Covid-19.” New England Journal of Medicine, vol. 384, no. 8, Feb. 2021, pp. 693–704,https://doi.org/10.1056/nejmoa2021436. |
![(16α)-21-[(Ethoxycarbonyl)oxy]-17-hydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione](/public/site/files/site_images/thumb_16alpha-21-ethoxycarbonyl-oxy-17-hydroxy-16-methylpregna-1-4-9-11-triene-3-20-dione47031.png)